• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

E3 连接酶 HUWE1 抑制作为一种治疗策略,针对多发性骨髓瘤中的 MYC。

The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma.

机构信息

Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.

Department of Oncology and Metabolism, Sheffield Myeloma Research Team, Medical School, University of Sheffield, Sheffield, UK.

出版信息

Oncogene. 2020 Jul;39(27):5001-5014. doi: 10.1038/s41388-020-1345-x. Epub 2020 Jun 10.

DOI:10.1038/s41388-020-1345-x
PMID:32523091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7329634/
Abstract

Proteasome inhibitors have provided a significant advance in the treatment of multiple myeloma (MM). Consequently, there is increasing interest in developing strategies to target E3 ligases, de-ubiquitinases, and/or ubiquitin receptors within the ubiquitin proteasome pathway, with an aim to achieve more specificity and reduced side-effects. Previous studies have shown a role for the E3 ligase HUWE1 in modulating c-MYC, an oncogene frequently dysregulated in MM. Here we investigated HUWE1 in MM. We identified elevated expression of HUWE1 in MM compared with normal cells. Small molecule-mediated inhibition of HUWE1 resulted in growth arrest of MM cell lines without significantly effecting the growth of normal bone marrow cells, suggesting a favorable therapeutic index. Studies using a HUWE1 knockdown model showed similar growth inhibition. HUWE1 expression positively correlated with MYC expression in MM bone marrow cells and correspondingly, genetic knockdown and biochemical inhibition of HUWE1 reduced MYC expression in MM cell lines. Proteomic identification of HUWE1 substrates revealed a strong association of HUWE1 with metabolic processes in MM cells. Intracellular glutamine levels are decreased in the absence of HUWE1 and may contribute to MYC degradation. Finally, HUWE1 depletion in combination with lenalidomide resulted in synergistic anti-MM activity in both in vitro and in vivo models. Taken together, our data demonstrate an important role of HUWE1 in MM cell growth and provides preclinical rationale for therapeutic strategies targeting HUWE1 in MM.

摘要

蛋白酶体抑制剂在多发性骨髓瘤 (MM) 的治疗中取得了重大进展。因此,人们越来越感兴趣的是开发针对泛素蛋白酶体途径中的 E3 连接酶、去泛素酶和/或泛素受体的策略,旨在实现更高的特异性和降低副作用。先前的研究表明,E3 连接酶 HUWE1 在调节 c-MYC 中发挥作用,c-MYC 是 MM 中经常失调的癌基因。在这里,我们研究了 HUWE1 在 MM 中的作用。我们发现 MM 中 HUWE1 的表达升高,与正常细胞相比。小分子介导的 HUWE1 抑制导致 MM 细胞系生长停滞,而对正常骨髓细胞的生长没有明显影响,表明治疗指数良好。使用 HUWE1 敲低模型的研究表明类似的生长抑制。HUWE1 表达与 MM 骨髓细胞中的 MYC 表达呈正相关,相应地,HUWE1 的遗传敲低和生化抑制降低了 MM 细胞系中的 MYC 表达。HUWE1 底物的蛋白质组学鉴定表明 HUWE1 与 MM 细胞中的代谢过程密切相关。在没有 HUWE1 的情况下,细胞内谷氨酰胺水平降低,可能导致 MYC 降解。最后,HUWE1 耗竭与来那度胺联合使用在体外和体内模型中均产生协同抗 MM 活性。总之,我们的数据表明 HUWE1 在 MM 细胞生长中起着重要作用,并为针对 MM 中 HUWE1 的治疗策略提供了临床前依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b077/7329634/44d494132acc/41388_2020_1345_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b077/7329634/59abaf53c59e/41388_2020_1345_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b077/7329634/4e06783cc18c/41388_2020_1345_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b077/7329634/8eacef0f5e4a/41388_2020_1345_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b077/7329634/39e9a00fe608/41388_2020_1345_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b077/7329634/5091b1ec0c57/41388_2020_1345_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b077/7329634/44d494132acc/41388_2020_1345_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b077/7329634/59abaf53c59e/41388_2020_1345_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b077/7329634/4e06783cc18c/41388_2020_1345_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b077/7329634/8eacef0f5e4a/41388_2020_1345_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b077/7329634/39e9a00fe608/41388_2020_1345_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b077/7329634/5091b1ec0c57/41388_2020_1345_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b077/7329634/44d494132acc/41388_2020_1345_Fig6_HTML.jpg

相似文献

1
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma.E3 连接酶 HUWE1 抑制作为一种治疗策略,针对多发性骨髓瘤中的 MYC。
Oncogene. 2020 Jul;39(27):5001-5014. doi: 10.1038/s41388-020-1345-x. Epub 2020 Jun 10.
2
Targeting of the E3 ubiquitin-protein ligase HUWE1 impairs DNA repair capacity and tumor growth in preclinical multiple myeloma models.靶向 E3 泛素连接酶 HUWE1 可破坏临床前多发性骨髓瘤模型的 DNA 修复能力并抑制肿瘤生长。
Sci Rep. 2020 Oct 28;10(1):18419. doi: 10.1038/s41598-020-75499-3.
3
The E3 ubiquitin ligase HUWE1 acts through the N-Myc-DLL1-NOTCH1 signaling axis to suppress glioblastoma progression.E3 泛素连接酶 HUWE1 通过 N-Myc-DLL1-NOTCH1 信号轴发挥作用,抑制胶质母细胞瘤的进展。
Cancer Commun (Lond). 2022 Sep;42(9):868-886. doi: 10.1002/cac2.12334. Epub 2022 Jul 18.
4
Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase.使用HUWE1泛素连接酶的小分子抑制剂对MYC功能进行肿瘤细胞特异性抑制。
EMBO Mol Med. 2014 Dec;6(12):1525-41. doi: 10.15252/emmm.201403927.
5
Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.HUWE1/c-MYC 通路的失调赋予了子宫颈癌对 BET 溴结构域抑制剂 GS-626510 的敏感性。
Gynecol Oncol. 2020 Sep;158(3):769-775. doi: 10.1016/j.ygyno.2020.06.484. Epub 2020 Jun 26.
6
HUWE1 upregulation has tumor suppressive effect in human prostate cancer cell lines through c-Myc.HUWE1 的上调通过 c-Myc 对人前列腺癌细胞系具有肿瘤抑制作用。
Biomed Pharmacother. 2018 Oct;106:309-315. doi: 10.1016/j.biopha.2018.06.058. Epub 2018 Jul 11.
7
Tobramycin suppresses HUWE1 degradation to control MCL-1 stability during tumour development.妥布霉素抑制 HUWE1 的降解,从而在肿瘤发展过程中控制 MCL-1 的稳定性。
Clin Exp Pharmacol Physiol. 2020 Sep;47(9):1600-1610. doi: 10.1111/1440-1681.13335. Epub 2020 Jun 1.
8
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.针对溴结构域和额外末端基序家族蛋白的蛋白靶向嵌合分子对多发性骨髓瘤的临床前模型具有活性。
Leukemia. 2018 Oct;32(10):2224-2239. doi: 10.1038/s41375-018-0044-x. Epub 2018 Mar 27.
9
Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival.组蛋白去甲基化酶JMJD1A对c-Myc表达的调控对于前列腺癌细胞的生长和存活至关重要。
Oncogene. 2016 May 12;35(19):2441-52. doi: 10.1038/onc.2015.309. Epub 2015 Aug 17.
10
Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.抑制鞘氨醇激酶 2 可下调 c-Myc 和 Mcl-1 的表达,并诱导多发性骨髓瘤细胞凋亡。
Blood. 2014 Sep 18;124(12):1915-25. doi: 10.1182/blood-2014-03-559385.

引用本文的文献

1
E3 ubiquitin ligases in signaling, disease, and therapeutics.信号传导、疾病与治疗中的E3泛素连接酶
Trends Biochem Sci. 2025 Sep 11. doi: 10.1016/j.tibs.2025.07.009.
2
Regulatory role of E3 ubiquitin ligases in multiple myeloma: from molecular mechanisms to therapeutic strategies.E3泛素连接酶在多发性骨髓瘤中的调控作用:从分子机制到治疗策略
Front Cell Dev Biol. 2025 Jul 30;13:1620097. doi: 10.3389/fcell.2025.1620097. eCollection 2025.
3
Inhibition of tumor growth using A conjugated nanobody that specifically targets c-MYC.使用特异性靶向c-MYC的A共轭纳米抗体抑制肿瘤生长。

本文引用的文献

1
Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas.蛋白基因组学分析揭示了甲状腺乳头状癌中的 TFG-RET 基因融合和可用药靶。
Nat Commun. 2020 Apr 28;11(1):2056. doi: 10.1038/s41467-020-15955-w.
2
Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.硼替佐米和其他蛋白酶体抑制剂引起的周围神经毒性:从发病机制到治疗。
J Peripher Nerv Syst. 2019 Oct;24 Suppl 2:S52-S62. doi: 10.1111/jns.12338.
3
Non-proteolytic ubiquitination of Hexokinase 2 by HectH9 controls tumor metabolism and cancer stem cell expansion.
Oncogene. 2025 Jul 6. doi: 10.1038/s41388-025-03486-x.
4
Integrative Analysis of Bulk Multiomics and Single-Cell Transcriptomics Elucidates Age-Related Molecular Landscape Alterations in Cervical Cancer.批量多组学与单细胞转录组学的综合分析揭示了宫颈癌中与年龄相关的分子景观改变。
Ann Surg Oncol. 2025 May 26. doi: 10.1245/s10434-025-17464-w.
5
Targeting protein synthesis pathways in MYC-amplified medulloblastoma.靶向MYC扩增的髓母细胞瘤中的蛋白质合成途径。
Discov Oncol. 2025 Jan 8;16(1):23. doi: 10.1007/s12672-025-01761-7.
6
The role of E3 ubiquitin ligases in bone homeostasis and related diseases.E3泛素连接酶在骨稳态及相关疾病中的作用。
Acta Pharm Sin B. 2023 Oct;13(10):3963-3987. doi: 10.1016/j.apsb.2023.06.016. Epub 2023 Jul 6.
7
The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target.《NF-κB药典:制服顽固靶点的新策略》
Biomedicines. 2022 Sep 8;10(9):2233. doi: 10.3390/biomedicines10092233.
8
The giant E3 ligase HUWE1 is linked to tumorigenesis, spermatogenesis, intellectual disability, and inflammatory diseases.巨 E3 连接酶 HUWE1 与肿瘤发生、精子发生、智力障碍和炎症性疾病有关。
Front Cell Infect Microbiol. 2022 Jul 22;12:905906. doi: 10.3389/fcimb.2022.905906. eCollection 2022.
9
A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing.环状 RNA 结合蛋白 HNRNPU 编码的一种新型蛋白通过调控骨髓微环境和可变剪接促进多发性骨髓瘤进展。
J Exp Clin Cancer Res. 2022 Mar 8;41(1):85. doi: 10.1186/s13046-022-02276-7.
10
CRISPR screening of E3 ubiquitin ligases reveals Ring Finger Protein 185 as a novel tumor suppressor in glioblastoma repressed by promoter hypermethylation and miR-587.CRISPR 筛选 E3 泛素连接酶揭示 Ring Finger Protein 185 作为胶质母细胞瘤的新型肿瘤抑制因子,受启动子高甲基化和 miR-587 抑制。
J Transl Med. 2022 Feb 19;20(1):96. doi: 10.1186/s12967-022-03284-z.
HectH9 通过非蛋白水解泛素化调控己糖激酶 2 控制肿瘤代谢和肿瘤干细胞扩增。
Nat Commun. 2019 Jun 14;10(1):2625. doi: 10.1038/s41467-019-10374-y.
4
Multiple myeloma: Every year a new standard?多发性骨髓瘤:每年都有新标准?
Hematol Oncol. 2019 Jun;37 Suppl 1(Suppl 1):62-65. doi: 10.1002/hon.2586.
5
CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy.CD38 在人类多发性骨髓瘤细胞中的腺苷能途径和代谢重编程中的作用:从基础科学到治疗的同步见解。
Front Immunol. 2019 Apr 24;10:760. doi: 10.3389/fimmu.2019.00760. eCollection 2019.
6
Carfilzomib for relapsed and refractory multiple myeloma.卡非佐米用于复发难治性多发性骨髓瘤
Cancer Manag Res. 2019 Apr 2;11:2663-2675. doi: 10.2147/CMAR.S150653. eCollection 2019.
7
Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma.代谢改变以及在多发性骨髓瘤治疗中靶向代谢途径的潜力。
J Cancer Metastasis Treat. 2019;5. doi: 10.20517/2394-4722.2019.05. Epub 2019 Apr 3.
8
The Influence of Metabolism on Drug Response in Cancer.代谢对癌症中药物反应的影响
Front Oncol. 2018 Nov 2;8:500. doi: 10.3389/fonc.2018.00500. eCollection 2018.
9
The power of proteasome inhibition in multiple myeloma.蛋白酶体抑制在多发性骨髓瘤中的作用。
Expert Rev Proteomics. 2018 Dec;15(12):1033-1052. doi: 10.1080/14789450.2018.1543595. Epub 2018 Nov 14.
10
Ixazomib for the treatment of multiple myeloma.伊沙佐米治疗多发性骨髓瘤。
Expert Opin Pharmacother. 2018 Dec;19(17):1949-1968. doi: 10.1080/14656566.2018.1528229. Epub 2018 Nov 13.